Front-line hormonal therapy for patients with advanced breast cancer: a community oncology research program.
Megestrol acetate was administered as first-line therapy to 152 patients with advanced breast cancer. Forty-three of 136 evaluable patients (32%) obtained an objective response (95% confidence interval, 24% to 40%). Toxicity was minimal, with only 4 patients requiring dose reduction. Megestrol acetate is an effective, well-tolerated agent in previously untreated patients with advanced breast cancer.
Smalley
R V
RV
Department of Human Oncology, University of Wisconsin School of Medicine, Madison.
Sigal
R B
RB
Anderson
S
S
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008535:Megestrol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate
D008535:Megestrol; D019290:Megestrol Acetate